Evidence map›Paper›PMID 42466546›Full record

ArticleArchiv der Pharmazie2026

Thiazole-Derived Dual EGFR/CDK-2 Inhibitors: Rational Design, Synthesis, In Vitro Anticancer Evaluation, Mechanistic Profiling, and Computational Binding Analysis.

Rowida Nasr, Mohamed S Nafie, Hesham Haffez, Mohamed Ahmed A Moustafa, Mohamed M El-Kerdawy, Ahmed R Ali

Abstract read
In one paragraph

Article in Archiv der Pharmazie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rowida NasrDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Mohamed S NafieDepartment of Chemistry, College of Sciences, University of Sharjah, Sharjah, UAE.ORCID https://orcid.org/0000-0003-4454-6390
Hesham HaffezBiochemistry and Molecular Biology Department, Faculty of Pharmacy, Capital University (formerly Helwan University), Cairo, Egypt.ORCID https://orcid.org/0000-0002-9924-2063
Mohamed Ahmed A MoustafaDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Mohamed M El-KerdawyDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Ahmed R AliDepartment of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.ORCID https://orcid.org/0000-0002-1719-6199

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New series of thiazole analogues were designed, synthesized, and tested for their potential anticancer activity. All the synthesized compounds were biologically tested against HCT-116 and MCF-7 cell lines. Compounds 14d, 14h, and 14i were determined to be the most active members in this series against HCT-116 cancer cell lines with a considerable safety profile. The three lead compounds were further investigated for their inhibitory activities against EGFR and CDK-2. Compound 14i exhibited the most potent inhibition, with IC

Indexed as

Antineoplastic AgentsCyclin-Dependent Kinase 2Drug DesignProtein Kinase InhibitorsThiazolesApoptosisCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorErbB ReceptorsHCT116 CellsHumansMCF-7 CellsMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsCDK2 protein, humanCyclin-Dependent Kinase 2EGFR protein, humanErbB ReceptorsProtein Kinase InhibitorsThiazolesanticancerapoptosiscell cycle arrestdual EGFR/CDK‐2 inhibitionmolecular dockingmolecular dynamics simulationnetwork pharmacologysynthesisthiazole

Identifiers

PMID42466546
PMCPMC13377680

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.